Clinical trials: Irinotecan
Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00562419
- Testing
- CT-322, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
Colorectal Neoplasms, Liver Neoplasms
Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone.
- Trial name
- NCT00143403
- Testing
- Irinotecan + 5 FU + folinic acid, Folinic Acid + 5 FU
- Where
- 66 sites in Belgium, Denmark and 14 more
- Volunteers
- 321 people
- Sponsor
- Pfizer
Colorectal Neoplasms, Liver Neoplasms
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be performed.
- Trial name
- NCT00106054
- Testing
- Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Colorectal Cancer
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan…
- Trial name
- NCT00063141
- Testing
- cetuximab, Irinotecan
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 1,302 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Carcinoma
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung…
- Trial name
- NCT00143455
- Testing
- Etoposide + cisplatin, Irinotecan + cisplatin
- Where
- 67 sites in Austria, Belgium and 11 more
- Volunteers
- 485 people
- Sponsor
- Pfizer
Pediatric Solid Tumors
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)
The purpose of this study is to determine the long term safety of patients with refractory solid tumors who have experienced clinical benefit after at least 6 cycles of treatment in BMS Protocol CA124-001 or CA124-002.
- Trial name
- NCT00990912
- Testing
- Carboplatin, Irinotecan
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Neoplasms
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral).
- Trial name
- NCT00101686
- Testing
- Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab
- Where
- 175 sites in United States, Australia and 2 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Unspecified Adult Solid Tumor, Chemotherapy
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.
- Conditions
- Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction, Neoplasms, Solid Tumor
- Trial name
- NCT00037804
- Testing
- Irinotecan
- Where
- 4 sites in United States
- Sponsor
- Pfizer
Breast Neoplasms
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a…
- Trial name
- NCT00072852
- Testing
- Irinotecan
- Where
- 66 sites in United States, Argentina and 3 more
- Volunteers
- 134 people
- Sponsor
- Pfizer
Neoplasm Metastasis, Colorectal Neoplasms
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences.
- Trial name
- NCT00037180
- Testing
- Celecoxib, Irinotecan, 5-fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 212 people
- Sponsor
- Pfizer
Carcinoma, Hepatocellular
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.
- Trial name
- NCT00635323
- Testing
- Irinotecan plus capecitabine
- Where
- 9 sites in China, Hong Kong and 2 more
- Volunteers
- 73 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell…
- Trial name
- NCT00139711
- Testing
- Irinotecan, Docetaxel
- Where
- 15 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Pfizer
Colorectal Cancer
A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as…
- Trial name
- NCT00034502
- Testing
- ALIMTA, irinotecan
- Where
- 9 sites in United States, Germany
- Sponsor
- Eli Lilly and Company
Solid Tumors
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential.
- Trial name
- NCT00044785
- Testing
- triacetyluridine, fluorouracil, leucovorin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wellstat Therapeutics